REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:
An audio webcast of the fireside chat presentation will be available on the investors’ page of the Coherus website at http://investors.coherus.com. Please access the website prior to the start of the presentation to ensure a timely connection to the webcast. The webcast will be archived on the Coherus website for 30 days.
Coherus Contact Information:
Marek Ciszewski, SVP Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.19 |
| Daily Change: | 0.03 2.59 |
| Daily Volume: | 953,423 |
| Market Cap: | US$138.310M |
August 07, 2025 May 12, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
